GLP1R and type 2 diabetes mellitus: Tirzepatide (a new dual GLP-1/GIP agonist) displayed better and clinically relevant hemoglobin A1c (HbA1c) reduction when compared to insulin glargine in persons with type 2 diabetes (T2D) and increased cardiovascular risk, with a reduced incidence of hypoglycemia [8].